Outcomes following calcium channel blocker exposures reported to a poison information center by Christensen, Mikkel B et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Outcomes following calcium channel blocker exposures reported to a poison
information center
Christensen, Mikkel B; Petersen, Kasper M; Bøgevig, Søren; Al-Gibouri, Salam; Jimenez-
Solem, Espen; Dalhoff, Kim P; Petersen, Tonny S; Andersen, Jon T
Published in:
B M C Clinical Pharmacology
DOI:
10.1186/s40360-018-0271-9
Publication date:
2018
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY
Citation for published version (APA):
Christensen, M. B., Petersen, K. M., Bøgevig, S., Al-Gibouri, S., Jimenez-Solem, E., Dalhoff, K. P., ... Andersen,
J. T. (2018). Outcomes following calcium channel blocker exposures reported to a poison information center. B
M C Clinical Pharmacology, 19(1), 1-8. [78]. https://doi.org/10.1186/s40360-018-0271-9
Download date: 03. Feb. 2020
RESEARCH ARTICLE Open Access
Outcomes following calcium channel
blocker exposures reported to a poison
information center
Mikkel B. Christensen1,2* , Kasper M. Petersen1, Søren Bøgevig1, Salam Al-Gibouri1, Espen Jimenez-Solem1,2,
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Abstract
Background: Calcium channel blockers (CCBs) are widely used drugs that have a narrow therapeutic index. Even
minor overdoses must be treated in-hospital due to the risk of severe hypotension and bradycardia. We aimed to
describe trends in CCB use and overdoses in Denmark.
Methods: Data on enquiries concerning CCBs reported to the Danish Poisons Information Center (DPIC) from
January 2009 to January 2015 was coupled with data on hospitalization and mortality obtained from Danish
National Registers. We obtained data on the general use of CCBs in Denmark and retrieved medical charts on fatal
cases.
Results: From a total of 126,987 enquiries to the DPIC in 2009–2014 we identified 339 CCB unique exposures (3‰
of all). Children < 5 years accounted for 20% all exposures and these were classified as ‘intake during playing’ (61%)
and ‘medication errors’ (39%). Among adults ‘suicidal poisonings’ (58%), and ‘medication errors’ (34%) were most
frequent. A majority (81%) of exposures led to hospital admission. Seven patients (2%) died from the CCB exposure
and all were adults with ‘suicidal poisoning’. Amlodipine accounted for 95% of all CCB prescriptions, was involved
in 71% of enquiries and in 29% of fatalities. Verapamil accounted for 3% of prescriptions, was involved in 13% of
enquiries and 57% of fatalities.
Conclusion: Four fifths of enquiries to the DPIC result in hospitalization and one fifth concern small children.
Mortality were infrequent and occurred only in adults with suicidal exposures and with and an overrepresentation
of verapamil exposures.
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Background
Calcium channel blockers (CCBs) are widely used
drugs indicated for the treatment of cardiovascular
disease and migraine. CCBs have a narrow thera-
peutic index, and consequently even minor overdoses
have to be treated in-hospital due to the risk of se-
vere hypotension and bradycardia [1, 2]. All of the
CCBs block L-type voltage gated calcium channels,
but individual agents differ in chemical structure and
tissue selectivity [3]. At therapeutic doses CCBs be-
longing to the dihydropyridine class (e.g. amlodipine
and felodipine) are primarily affecting calcium chan-
nels in the smooth muscle in peripheral vessels,
whereas non-dihydropyridine agents (verapamil and
diltiazem) are also affecting calcium channels in the
heart [2, 3]. Tissue selectively has been reported to
be attenuated with increasing doses, but nonetheless,
non-dihydropyridine overdoses often leads to various
degrees of conduction block and are therefore con-
sidered most dangerous [1, 2]. Metabolic and central
nervous system (CNS) disturbances are also seen
after CCB overdoses, but the cause of death after
CCB toxicity is usually presumed to be circulatory
collapse [1–4]. Thus, advising about and caring for
patients, who have ingested CCBs deliberately or un-
intentionally is a challenging health care task; and
there is limited information on the pharmacoepide-
miology and outcomes of overdoses with CCBs. The
objectives of this study are to describe trends in the
general use of CCBs and to describe causes and con-
sequences of CCB poisonings based on data from
the Danish Poisons Information Center (DPIC), Da-
nish national registers and medical charts.
Methods
Data
In this retrospective study we identified all patients
poisoned with CCBs from the DPIC-database from
January 1st, 2009 to December 31st 2014. The DPIC
is a telephone-based, 24-h service providing informa-
tion on a national level to guide the public and
health care professionals on all aspects related to
acute poisonings including the management of the
poisoned patient. All telephone enquiries to the
DPIC are registered in a database with information
on the suspected poisoning. The following are re-
corded: patient data including the unique personal
identification number, a description of the poisoning
(poison, amount in DDD, mode of exposure, etc.),
clinical status of the patient, and the cause of poi-
soning. The cause of poisoning was divided into ‘sui-
cidal intake’ or ‘accidental intake’, ‘abuse’ or ‘other’.
Accidental intake includes ‘intake during playing’
and ‘medication errors’ e.g. incorrect dosage or drug,
accident, or confusion of pills.
In the DPIC-database we identified all inquiries con-
cerning CCBs by searching for synonyms of CCBs
combined with all generic and brand names of CCBs
marketed in Denmark during the study period. Only
records with a complete personal identification num-
ber and a registration of a possible CCB overdose or
poisoning were included in the study. The DPIC re-
cords of CCB exposures were then linked with hos-
pital records from the Danish National Hospital
Register [5] and information on death was retrieved
from the Danish Register of Causes of Death [6]. All
records were linked using the unique Danish personal
identification number [7], which all persons living in
Denmark get at birth or following immigration to
Denmark.
The National Hospital Registry contains informa-
tion on all hospitalizations and outpatient visits in
Denmark, including 99% of all discharge records,
length of hospital stay and discharge diagnoses
(International Classification of Diseases 10th Edi-
tion (ICD-10) Danish revision) [5]. The Danish
Register of Causes of Death holds information on
all deaths in Denmark including place, time, and
cause of death classified using ICD-10 Danish revi-
sion codes [6].
Sales numbers for CCBs expressed in Defined Daily
Doses (DDDs) in the primary and secondary sectors in
Denmark were extracted as additional information from
the online database MEDSTAT [8].
Detailed medical charts for the fatal cases (identi-
fied through national registers) were retrieved from
the hospital departments, where these patients were
admitted.
Statistics
All analyses and data management were performed
using SAS statistical software version 9.4 (SAS Insti-
tute Inc., Cary, NC, USA). Frequency distributions
comparisons were analysed with Fisher’s exact test.
For all analyses, a two-sided value of p < 0.05 was
considered statistically significant, and all odds ratios
are presented with 95% confidence intervals. Graph-
ical presentation was prepared using Graphpad Prism
version 7.02 (La Jolla, CA, USA).
Results
From a total of 126,987 enquiries to the DPIC in
2009–2014 we identified 339 records (3‰ of all)
concerning patients with a CCB exposure, where
outcome data was available through the national
registries (Fig. 1).
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Description of population
Age and gender distribution
The age distribution among patients with a CCB expos-
ure was bimodal with a peak in the preschool children
and in adults aged 40–80 years (Fig. 2).
Children (i.e. boys and girls < 16 years) accounted
for 24% of all CCB enquires (N = 78), and the youn-
gest age group 0–5 years accounted for 20% all expo-
sures (N = 69). There were slightly more boys (56%)
among exposed children, whereas females were the
majority in individuals above 16 years of age (61%)
(p < 0.01).
Reason for exposure
Suicidal exposures accounted for 46% of all en-
quiries. However, the reason for exposure differed
across age groups. Only 6% (N = 5) of the children’s
cases were caused by suicidal exposures, all concern-
ing girls aged 13–15 years. The major reason for ex-
posure (85%) in children were ‘medication errors’
(40%) or ‘intake during playing’ (54%). In the youn-
gest age (i.e. < 5 years) group reasons for exposure
were ‘intake during playing’ (61%) and ‘medication
errors’ (39%). The age group 16–65 years had a high
proportion (71%) of suicidal exposures compared to
the age group above 65 years (35%) (p < 0.0001). The
accidental exposures in the above 65 years age-group
were most often (55%) ‘medication errors’.
CCBs involved in poisonings and their sales in Denmark
Single drug exposures constituted 35% of all cases, but 65% of
exposures in children. The majority (78%) of accidental expo-
sures concerned intake of only one CCB, whereas the majority
(84%) of suicidal exposures the CCBs were taken with other
substances (i.e. mixed exposures). Among all enquiries (i.e.
both suicidal and accidental) concerning CCBs, amlodipine
was the most common and was involved in 72% (N=249) of
the cases, whereas verapamil was involved in 13% (N=45),
felodipine in 5% (N= 16), and diltiazem in 5% (N=16).
From 2009 to 2015, the sale of dihydropyridine CCBs
increased, whereas sales of verapamil and diltiazem
slightly decreased (Fig. 3a). The population-corrected
frequency of enquiries concerning CCBs were 61 en-
quiries per million citizens (Fig. 3, Table 1 in appendix),
with an increasing trend in enquiries over the study
period (Fig. 3b).
Outcome of exposure
Hospital admission
A majority (81%) of cases were admitted to a hospital.
Children were admitted in 88% of exposures, and
adults were admitted in 78% of exposures. In adults
with clear anamnestic information on exposure dose
the length of in-hospital stay increased with higher
DDD-intake/exposure of both dihydropyridine and
non-dihydropyridine CCBs (Fig. 4). In children, the
anamnestic information on dosage was too uncertain
(e.g. worst-case scenarios) for the purpose of relating
DDDs to length of hospital stay. In children the
length of in-hospital stay had a median value of 1 day
(range 0–4 days): Dihydropyridines accounted for 25
exposures in children that subdivided into: 4 expo-
sures leading to: 0 days in-hospital stay; 17 exposures:
1 day; 3 exposures: 2 days; 1 exposure: 4 days. Verap-
amil intake by children accounted for six exposures: 2
Fig. 2 Age distribution among CCB exposures registered by the
Danish Poison Information Center from 2009 to 2014
Fig. 1 Flow Chart for patient inclusion
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exposures led to 1 day in-hospital stay and 4 expo-
sures led to 3 days in-hospital stay.
Mortality following CCB exposure
Seven patients (2%) died within 30 days after CCB ex-
posure, but one of the patients did not die from CCB
poisoning (Table 2 in Appendix presents details from
these lethal cases). Mortality occurred only in adults
with suicidal exposures, and the lethal cases were all
mixed exposures. The CCB’s involved were verapamil
(N = 4), amlodipine (N = 2) or felodipine (N = 1). Of
the four adults who died after verapamil exposure, in-
formation on intake was available for two, who
ingested 25 and 100 DDDs, respectively. There were
no deaths among 120 enquiries concerning an
isolated intake of dihydropyridine CCB (both adults
and children) – even after a severe overdose (e.g. in 6
patients with exposures exceeding 100 DDDs).
Discussion
We report that despite enquiries to the DPIC concerning
CCBs being relatively infrequent, four-fifth of exposures
resulted in hospitalization and 2% led to death. In that
context, we find it reassuring that mortality only oc-
curred in adults with suicidal intent. One fourth of expo-
sures concerned children, and there were no deaths or
prolonged in-hospital stays in pre-school children.
Our data may therefore be used to question the relatively
cautious guidelines for out-of-hospital management of CCB
overdoses recommending that intake of amlodipine and
Fig. 3 a Sales in WHO defined daily doses (DDD) of calcium Channel Blockers in Denmark and b) CCB exposures registered by the Danish Poison
Information Center from 2009 to 2014
Fig. 4 Association of dose of CCB exposure (expressed in DDD) with duration of in-hospital stay in adults for a) the dihydropyridines (mostly
amlodipine) or b) non-dihydropyridines (verapamil)
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felodipine doses of 0.3mg/kg and 10mg (2 DDDs) in chil-
dren and adults, respectively, should be referred to the
emergency department [1]. Our data is quite accurate on
length of hospital stay and there were only very few
in-hospital stays > 1 day in children after accidental dihydro-
pyridine or verapamil overdoses. A similar finding was also
reported by others, where intake of a relatively large amount
of CCBs did not give rise to major symptoms in children
under the age of 6 years [9, 10]. However, our data material
is not precise enough on symptomatology or large enough
to contradict reports of significant hypotension or severe
toxicity even after minor accidental exposures ( [1, 11].
The finding of no fatalities in adults following acciden-
tal exposures (i.e. not counting suicidal or abuse expo-
sures), are in line with other reports. Generally deaths
have only rarely been reported following unintentional
intake of CCBs and often other important complicating
factors may have played important roles for the fatal
course e.g. serious co-exposures such as other cardioac-
tive drugs, co-morbidity such as heart failure, or very
low age [1, 12]. It is noteworthy that there were no
deaths in adults following isolated intake of dihydropyri-
dines, which are by far the most widely used CCBs, even
after intake of up to 200 DDDs. In contrast, verapamil
was involved in four out of seven deaths despite only be-
ing involved in 13% of enquiries and in 3–5% of the
total CCB sale in Denmark. Thus, our results seem to
corroborate the larger risk attributed to verapamil also
reported by others [1, 4, 13]. Our thorough review of
the fatal cases underlines the differences between verap-
amil and dihydropyridines in toxicity: All verapamil
overdoses presented with severe cardiotoxicity and con-
duction abnormalities (i.e. 3rd degree atrioventricular-
and/or left bundle branch blocks, pulseless electric ac-
tivity) that deteriorated after arrival and led to death
within 3 days (Table 2 in Appendix). Of the two fatal
dihydropyridine cases (one amlodipine and one felodi-
pine), the felodipine exposure did not present with or
develop in-hospital severe cardiac disturbances but died
after 8 days of hypoxic-ischemic brain damage (devel-
oped before arrival to the hospital and likely related to
co-ingestion of codeine and quinine). The fatal amlodi-
pine exposure died of severe cardiotoxicity but had also
co-ingested metoprolol and enalapril – whereof both,
but in particular metoprolol is known to exert synergis-
tic cardiodepressive effects with CCBs.
A particular problem evident from the fatal cases pre-
sented in Table 2 in Appendix is the apparent lack of
alignment with current treatment recommendations [14],
which in all cases was advocated by the DPIC. Particular,
therapies such as high-dose insulin (used in two of six
cases), high-dose glucagon (used in three of six cases), and
high-dose intravenous lipid emulsion (used in one of six
cases), seem underused. Findings of lack of adherence to
guidelines and poison center advice have also been re-
ported by others [15, 16].
Collectively, our findings correlate reasonably with other
publications describing CCB exposures [1, 9, 17–20]. How-
ever, there are some discrepancies worth noticing. Our rate
of hospital admission (81%) appears high compared to previ-
ous reports of approximately 50–73% hospital admissions fol-
lowing CCB exposures [1, 17] and may reflect the severity of
exposures reported to the DPIC, where approximately half of
the exposures were suicidal. Olson et al. [1] described death
to occur only after verapamil, nifedipine, and diltiazem and
Deters et al. [18] described death to occur most frequently
after diltiazem exposures. In our material, nifedipine and dil-
tiazem was only involved in few exposures and not involved
in fatal cases. This difference likely reflects the relatively infre-
quent use of nifedipine and diltiazem in Denmark, where
sales are decreasing for older dihydropyridines (e.g. nifedi-
pine) and non-dihydropyridines (verapamil and diltiazem).
Strengths and limitations
This study covers nationwide follow-up data in our study
population due to the completeness of the Danish National
Health Registers. Thus, we have reliable outcome data on
all patients studied. Nevertheless, the major limitations of
this study relate to the completeness of data: We identified
exposures through the enquiries to the DPIC, and therefore
these cases may not be representative all the CCB expo-
sures in Denmark; some exposures may be handled at
home or be hospitalized or die without contact to the
DPIC. Furthermore, as discussed previously we have limited
data on clinical symptoms and our data reflects the clinical
scenario in acute poisonings, thus anamnestic information
concerning exposures, i.e. dose and potential co-ingestants
are somewhat uncertain – and in this retrospective study
no formal validation (i.e. measurement of plasma concen-
tration etc.) of offending drugs could be performed.
Conclusion
From 2009 to 2014, the sale of dihydropyridine CCBs in-
creased in Denmark, whereas sales of verapamil and dilti-
azem slightly decreased. In the same period, enquiries to
the DPIC concerning CCBs were rare (3‰ of all en-
quiries), but often serious and with 80% resulting in
hospitalization. One fourth of exposures concerned chil-
dren and most of these were monoexposures. There were
no deaths among 120 enquiries concerning an isolated in-
take of dihydropyridine CCB (both adults and children) –
even after a severe overdose (e.g. in 6 patients with expo-
sures exceeding 100 DDDs). Amlodipine accounted for
95% of all CCB prescriptions, was involved in 71% of en-
quiries and in 29% of fatalities. Verapamil accounted for
3% of prescriptions, was involved in 13% of enquiries and
57% of fatalities. Mortality occurred in 2% (N = 7) and only
in adults with suicidal exposures.
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Table 1 Citizens, CCB-related enquiries, and CCB sales and in Denmark 2009–2014
Year 2009 2010 2011 2012 2013 2014
Danish population in persons 5,532,531 5,557,709 5,579,204 5,599,665 5,623,501 5,655,750
CCB related enquiries 40 52 57 44 61 89
Total CCB sale in DDD 148,626 159,483 168,374 174,585 179,149 182,916
Dihydropyridines sale in DDD (% of total CCB sale) 137,779 (93) 149,428 (94) 159,057 (94) 165,904 (95) 171,181 (96) 175,518 (96)
Amlodipine sale in DDD (% of total CCB sale) 110,792 (75) 122,425 (77) 131,922 (78) 138,074 (79) 142,678 (80) 146,330 (80)
Verapamil sale in DDD (% of total CCB sale) 7314 (4.9) 6940 (4.4) 6543 (3.9) 6201 (3.6) 5872 (3.3) 5566 (3.0)
Diltiazem sale in DDD (% of total CCB sale) 3409 (2.3) 3079 (1.9) 2764 (1.6) 2480 (1.4) 2096 (1.2) 1832 (1.0)
Appendix
Table 2 Fatal cases
Gender
and age
Comorbidity Anamnestic
drug exposure
(doses noted if
known)
Interval to
presentation
and death
post intake
Clinical presentation at
hospital
Time from intake to
admission if known) and
symptoms (GCS,
temperature,
hemodynamic, renal,
other
Paraclinical parameters
Arterial blood gas (pH,
base excess, lactate)
blood samples (e.g.
glucose, calcium,) and
ECGs
Treatment
Gastrointestinal decontamination (e.g.
gastric emptying, activated charcoal).
Inotropes, vasopressors and
vasoactive therapy (e.g. isoprenaline,
norepinephrine).
Other interventions (e.g. dialysis,
calcium, glucagon)
Female,
82 y
Morbus
Meniere.
Cardiovascular
disease.
Several
previous
suicidal
attempts.
Verapamil
24,000 mg (as
extended
release tablets
240 mg)
Escitalopram
280 mg
3 days 12 h after intake:
Somnolent.
BP 80/35 mmHg, HR 35
increasing to 50.
Anuria.
Muscle twitches and
cramps in the
extremities.
ABG: pH 7.33, BE −10.8,
lactate 1,6–3,2 mmol/l.
P-glucose 9.1 mmol/l,
P-calcium (ion)1.17
mmol/l
Increasing creatinine
ECG: Initially AV nodal
rhythm, atrial
fibrillation with LBBB
Gastric aspiration (without lavage)
without any tablets retrieved.
Activated charcoal - single dose.
Atropine, Isoprenaline,
norepinephrine (up to 0.56 μg/kg/
minute), epinephrine (up to 0.4 μg/
kg/minute).
Levosimendan.
Other: Plasmapheresis and CRRT,
temporary pacemaker (bradycardia),
non-invasive ventilation due to car-
bon dioxide retention
Male, 49
y
Anxiety
Periodic
Depression,
Epilepsy.
Verapamil (as
extended
release tablets
240 mg)
Quetiapine
Codeine
Acetaminophen
Tramadol
Topiramate
2 h Within 12 h after intake:
GCS 3. Temperature 32,5
°C. Seizure in ambulance,
BP low, cold and pale.
Low urine production.
ABG: pH 6.88, lactate
11.3 mmol/L.
ECG: ST-depression V2-
V6 turning into first
bradycardia, then PEA
and finally cardiac
arrest.
Gastric aspiration (without lavage)
with small amounts of tablets
retrieved. Activated charcoal - single
dose.
Endotracheal intubation
Atropine, epinephrine,
norepinephrine, phenylephrine,
Other: Sodium bicarbonate, calcium,
dobutamine, naloxone
After PEA: Glucagon, amiodarone,
infusion with insulin-glucose (high
dose).
Female
76 y
Obesity.
COPD.
Arterial
hypertension.
Anxiety
disorder,
Several
previous
suicidal
attempts.
Verapamil
Acetaminophen
ozaxepam
12 h Time unknown.
Admission status:
GCS 9. Temperature 32,7
°C.
BP 80/50 mmHg, HR 40
initially increases to 65.
AKI.
Myoglobin 1167 μg/L.
ABG: pH 7.2, BE 3,
lactate 2.4 mmol/L
P-glucose 16,1 mmol/L
ECG: Bradycardia, 3rd
degree AV-block, asys-
tole turning into car-
diac arrest.
(GID not performed)
Atropine, isoprenaline,
norepinephrine (up to 0.7 μg/kilo/
minute), epinephrine (0.4 μg/kilo/
minute).
Other: Flumazenil, N-acetylcysteine,
calcium, dopamine, sodium bicar-
bonate, naloxone.
Female
63 y
Unknown. Amlodipine 425
mg,
Metoprolol
4250 mg
Enalapril
2 days 6 h after intake:
Comatose.
MAP 50, HR 44 (SR), cold.
Anuria.
ABG: pH 7.1, BE-19.8,
lactate 17 mmol/L.
ECG: Atrioventricular
Junctional Rhythm
(25–40 bpm)
Gastric aspiration (without lavage)
with unknown result. Activated
charcoal - single dose.
Endotracheal intubation, controlled
ventilation with high oxygen
demand.
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Table 2 Fatal cases (Continued)
Gender
and age
Comorbidity Anamnestic
drug exposure
(doses noted if
known)
Interval to
presentation
and death
post intake
Clinical presentation at
hospital
Time from intake to
admission if known) and
symptoms (GCS,
temperature,
hemodynamic, renal,
other
Paraclinical parameters
Arterial blood gas (pH,
base excess, lactate)
blood samples (e.g.
glucose, calcium,) and
ECGs
Treatment
Gastrointestinal decontamination (e.g.
gastric emptying, activated charcoal).
Inotropes, vasopressors and
vasoactive therapy (e.g. isoprenaline,
norepinephrine).
Other interventions (e.g. dialysis,
calcium, glucagon)
Atropine, norepinephrine,
epinephrine, isoprenaline.
Levosimendan, Other: temporary
pacemaker, calcium infusion,
glucagon, intravenous lipid
emulsion.
Dialysis.
Female,
61 y
COPD.
Depression.
Multiple
previous
suicide
attempts.
Verapamil 6000
mg
Ramipril 150 mg
Ibuprofen 20 g
Zolpidem 200
mg
2 Time unknown.
Admission status:
Unconscious. Reacts to
pain. Mumbles.
Temperature 34,2 °C.
BP 60/ 35, HR 36, cold,
pale and sweaty.
Anuria.
ABG: pH 7.26, BE − 6,8,
lactate 11.1 mmol/L
ECG: Wide QRS-
complexes.
Activated charcoal - single dose.
Endotracheal intubation.
Atropine isoprenaline, noradrenaline,
adrenaline, dopamine, ephedrine.
Other: temporary pacemaker,
calcium, glucagon,
Calcium (bolus and infusion),
glucagon, insulin, flumazenil.
Dialysis.
After temperature increases to 39 °C:
Tazobactam/piperacillin,
ciprofloxacin, metronidazole.
Male, 83
y
Paranoid
psychosis
Cerebral
infarction
Dementia
Arterial
hypertension.
Aortic valve
insufficiency.
Felodipine
(as 5 mg tablets)
Acetaminophen
10 g
Baclofen
Quinine 4 g,
Acetylsalicylic
acid (as 75 mg
tablets)
8 days Time unknown.
Admission status:
Somnolence.
BP 111/45, HR 77
Urine production.
ABG: pH 7.24, BE 8
P-creatinine: 207
mmol/L
P-calcium (ion): 0,96
ECG: 1st degree AV
block,
Right bundle branch
block (pre-existing) (
(GID nor performed).
adrenalin, noradrenalin
Endotracheal intubation.
Other: calcium, sodium bicarbonate,
N-acetylcysteine.
Furosemide, labetalol.
Symptomatic treatment (morphine,
diazepam)
Male, 30
y
Depression
Hypertension
Amlodipine (as
10 mg tablets)
Acetylsalicylic
acid
(as 75 mg
tablets)
Ramipril
12 h Time unknown.
Admission status:
Awake and fully aware of
the situation. Nausea and
sweaty – otherwise as
usual.
P-salicylate 0.4 mmol/L
ECG: Normal
No further test -
patient leaves the
hospital.
Activated charcoal - single dose.
Patient leaves the hospital before any
other treatment is started. The patient
dies 12 h later of carbon monoxide
poisoning.
Abbreviations: ABG Arterial Blood Gas, COPD Chronic Obstructive Pulmonary Disease, CRRT Continous Renal Replacement Therapy, ECG ElectroCardioGram, GCS
Glasgow Coma Score, BE Base Excess, LBBB Left Bundle Branch Blockade, GID Gastrointestinal Decontamination
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